{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:32:06Z","timestamp":1793413926888,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["Intramural Research Program"],"award-info":[{"award-number":["Intramural Research Program"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Niacin has modest but overall favorable effects on plasma lipids by increasing high density lipoprotein cholesterol (HDL-C) and lowering triglycerides. Clinical trials, however, evaluating niacin therapy for prevention of cardiovascular outcomes have returned mixed results. Recent evidence suggests that the HDL proteome may be a better indicator of HDL\u2019s cardioprotective function than HDL-C. The objective of this study was to evaluate the effect of niacin monotherapy on HDL protein composition and function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A 20-week investigational study was performed with 11 participants receiving extended-release niacin (target dose\u2009=\u20092\u2009g\/day) for 16-weeks followed by a 4-week washout period. HDL was isolated from participants at weeks: 0, 16, and 20. The HDL proteome was analyzed at each time point by mass spectrometry and relative protein quantification was performed by label-free precursor ion intensity measurement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In this cohort, niacin therapy had typical effects on routine clinical lipids (HDL-C\u2009+\u200916%, q\u2009&lt;\u20090.01; LDL-C\u2009\u2212\u200920%, q\u2009&lt;\u20090.01; and triglyceride \u2212\u200915%, q\u2009=\u20090.1). HDL proteomics revealed significant effects of niacin on 5 proteins: serum amyloid A (SAA), angiotensinogen (AGT), apolipoprotein A-II (APOA2), clusterin (CLUS), and apolipoprotein L1 (APOL1). SAA was the most prominently affected protein, increasing 3-fold in response to niacin (q\u2009=\u20090.008). Cholesterol efflux capacity was not significantly affected by niacin compared to baseline, however, stopping niacin resulted in a 9% increase in efflux (q\u2009&lt;\u20090.05). Niacin did not impact HDL\u2019s ability to influence endothelial function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Extended-release niacin therapy, in the absence of other lipid-modifying medications, can increase HDL-associated SAA, an acute phase protein associated with HDL dysfunction.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12944-020-01350-3","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T06:44:32Z","timestamp":1597992272000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Effect of niacin monotherapy on high density lipoprotein composition and function"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9532-032X","authenticated-orcid":false,"given":"Scott M.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo J.","family":"Amar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kianoush","family":"Jeiran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Stagliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Staller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin P.","family":"Playford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nehal N.","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Vaisar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan T.","family":"Remaley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,21]]},"reference":[{"issue":"5","key":"1350_CR1","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","volume":"62","author":"T Gordon","year":"1977","unstructured":"Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronary heart disease. Am J Med. 1977;62(5):707\u201314.","journal-title":"Am J Med"},{"issue":"4","key":"1350_CR2","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1007\/s11883-014-0398-0","volume":"16","author":"SM Tariq","year":"2014","unstructured":"Tariq SM, Sidhu MS, Toth PP, Boden WE. HDL hypothesis: where do we stand now? Curr Atheroscler Rep. 2014;16(4):398.","journal-title":"Curr Atheroscler Rep"},{"issue":"1","key":"1350_CR3","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1161\/CIRCRESAHA.117.311978","volume":"122","author":"AR Tall","year":"2018","unstructured":"Tall AR, Rader DJ. Trials and tribulations of CETP inhibitors. Circ Res. 2018;122(1):106\u201312.","journal-title":"Circ Res"},{"issue":"Suppl","key":"1350_CR4","doi-asserted-by":"publisher","first-page":"S167","DOI":"10.1194\/jlr.R800097-JLR200","volume":"50","author":"JW Heinecke","year":"2009","unstructured":"Heinecke JW. The HDL proteome: a marker--and perhaps mediator--of coronary artery disease. J Lipid Res. 2009;50(Suppl):S167\u201371.","journal-title":"J Lipid Res"},{"issue":"10","key":"1350_CR5","doi-asserted-by":"publisher","first-page":"5239","DOI":"10.1021\/pr100520x","volume":"9","author":"SM Gordon","year":"2010","unstructured":"Gordon SM, Deng J, Lu JL, Davidson SW. Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J Proteome Res. 2010;9(10):5239\u201349.","journal-title":"J Proteome Res"},{"issue":"3","key":"1350_CR6","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1172\/JCI26206","volume":"117","author":"T Vaisar","year":"2007","unstructured":"Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest. 2007;117(3):746\u201356.","journal-title":"J Clin Invest"},{"issue":"1","key":"1350_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.tem.2010.10.001","volume":"22","author":"SM Gordon","year":"2011","unstructured":"Gordon SM, Hofmann S, Askew DS, Davidson WS. High density lipoprotein: it's not just about lipid transport anymore. Trends Endocrinol Metab. 2011;22(1):9\u201315.","journal-title":"Trends Endocrinol Metab"},{"key":"1350_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.atherosclerosis.2016.11.015","volume":"259","author":"SM Gordon","year":"2017","unstructured":"Gordon SM, Remaley AT. High density lipoproteins are modulators of protease activity: implications in inflammation, complement activation, and atherothrombosis. Atherosclerosis. 2017;259:104\u201313.","journal-title":"Atherosclerosis."},{"issue":"1","key":"1350_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nrcardio.2015.124","volume":"13","author":"RS Rosenson","year":"2016","unstructured":"Rosenson RS, Brewer HB, Ansell BJ, Barter P, Chapman MJ, Heinecke JW, et al. Dysfunctional HDL and atherosclerotic cardiovascular disease. Nat Rev Cardiol. 2016;13(1):48\u201360.","journal-title":"Nat Rev Cardiol"},{"issue":"6","key":"1350_CR10","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","volume":"8","author":"PL Canner","year":"1986","unstructured":"Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, et al. Fifteen year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8(6):1245\u201355.","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"1350_CR11","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","volume":"365","author":"WE Boden","year":"2011","unstructured":"Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255\u201367.","journal-title":"N Engl J Med"},{"issue":"3","key":"1350_CR12","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","volume":"371","author":"MJ Landray","year":"2014","unstructured":"Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203\u201312.","journal-title":"N Engl J Med"},{"key":"1350_CR13","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.atherosclerosis.2018.09.032","volume":"278","author":"SM Gordon","year":"2018","unstructured":"Gordon SM, Chung JH, Playford MP, Dey AK, Sviridov D, Seifuddin F, et al. High density lipoprotein proteome is associated with cardiovascular risk factors and atherosclerosis burden as evaluated by coronary CT angiography. Atherosclerosis. 2018;278:278\u201385.","journal-title":"Atherosclerosis."},{"issue":"12","key":"1350_CR14","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1038\/nbt.1511","volume":"26","author":"J Cox","year":"2008","unstructured":"Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol. 2008;26(12):1367\u201372.","journal-title":"Nat Biotechnol"},{"issue":"12","key":"1350_CR15","doi-asserted-by":"publisher","first-page":"2301","DOI":"10.1038\/nprot.2016.136","volume":"11","author":"S Tyanova","year":"2016","unstructured":"Tyanova S, Temu T, Cox J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. Nat Protoc. 2016;11(12):2301\u201319.","journal-title":"Nat Protoc"},{"issue":"3","key":"1350_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192616","volume":"13","author":"T Vaisar","year":"2018","unstructured":"Vaisar T, Couzens E, Hwang A, Russell M, Barlow CE, DeFina LF, et al. Type 2 diabetes is associated with loss of HDL endothelium protective functions. PLoS One. 2018;13(3):e0192616.","journal-title":"PLoS One"},{"issue":"3","key":"1350_CR17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41596-019-0128-8","volume":"14","author":"H Mi","year":"2019","unstructured":"Mi H, Muruganujan A, Huang X, Ebert D, Mills C, Guo X, et al. Protocol update for large-scale genome and gene function analysis with the PANTHER classification system (v.14.0). Nat Protoc. 2019;14(3):703\u201321.","journal-title":"Nat Protoc"},{"issue":"D1","key":"1350_CR18","doi-asserted-by":"publisher","first-page":"D419","DOI":"10.1093\/nar\/gky1038","volume":"47","author":"H Mi","year":"2018","unstructured":"Mi H, Muruganujan A, Ebert D, Huang X, Thomas PD. PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools. Nucleic Acids Res. 2018;47(D1):D419\u2013D26.","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"1350_CR19","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1161\/ATVBAHA.115.306268","volume":"36","author":"GE Ronsein","year":"2016","unstructured":"Ronsein GE, Hutchins PM, Isquith D, Vaisar T, Zhao X-QQ, Heinecke JW. Niacin therapy increases high-density lipoprotein particles and Total cholesterol efflux capacity but not ABCA1-specific cholesterol efflux in statin-treated subjects. Arterioscler Thromb Vasc Biol. 2016;36(2):404\u201311.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"8","key":"1350_CR20","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1194\/jlr.M059089","volume":"56","author":"T Vaisar","year":"2015","unstructured":"Vaisar T, Tang C, Babenko I, Hutchins P, Wimberger J, Suffredini AF, et al. Inflammatory remodeling of the HDL proteome impairs cholesterol efflux capacity. J Lipid Res. 2015;56(8):1519\u201330.","journal-title":"J Lipid Res"},{"issue":"9","key":"1350_CR21","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.114.001508","volume":"4","author":"R Yadav","year":"2015","unstructured":"Yadav R, Liu Y, Kwok S, Hama S, France M, Eatough R, et al. Effect of extended-release niacin on high-density lipoprotein (HDL) functionality, lipoprotein metabolism, and mediators of vascular inflammation in statin-treated patients. J Am Heart Assoc. 2015;4(9):e001508.","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"1350_CR22","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1161\/ATVBAHA.118.310979","volume":"38","author":"PG Wilson","year":"2018","unstructured":"Wilson PG, Thompson JC, Shridas P, McNamara PJ, Beer MC, Beer FC, et al. Serum amyloid a is an exchangeable Apolipoprotein. Arterioscler Thromb Vasc Biol. 2018;38(8):1890\u2013900.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"1350_CR23","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1161\/CIRCULATIONAHA.108.836346","volume":"121","author":"SA Sorrentino","year":"2009","unstructured":"Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, Bahlmann FH, et al. Endothelial-vasoprotective effects of high-density lipoprotein are impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation. 2009;121(1):110\u201322.","journal-title":"Circulation."},{"issue":"6","key":"1350_CR24","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/ndt\/gfh727","volume":"20","author":"G Wolf","year":"2005","unstructured":"Wolf G, Wenzel U, Jablonski K, Brundert M, Rinninger F. Angiotensin II down-regulates the SR-BI HDL receptor in proximal tubular cells. Nephrol Dial Transplant. 2005;20(6):1222\u20137.","journal-title":"Nephrol Dial Transplant"},{"issue":"11","key":"1350_CR25","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/BF02524284","volume":"31","author":"S Lund-Katz","year":"1996","unstructured":"Lund-Katz S, Murley YM, Yon E, Gillotte KL, Davidson WS. Comparison of the structural and functional effects of monomeric and dimeric human apolipoprotein A-II in high density lipoprotein particles. Lipids. 1996;31(11):1107\u201313.","journal-title":"Lipids."},{"issue":"13","key":"1350_CR26","doi-asserted-by":"publisher","first-page":"9713","DOI":"10.1074\/jbc.M610380200","volume":"282","author":"RA Silva","year":"2007","unstructured":"Silva RA, Schneeweis LA, Krishnan SC, Zhang X, Axelsen PH, Davidson WS. The structure of apolipoprotein A-II in discoidal high density lipoproteins. J Biol Chem. 2007;282(13):9713\u201321.","journal-title":"J Biol Chem"},{"issue":"7","key":"1350_CR27","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1194\/jlr.M075382","volume":"58","author":"JT Melchior","year":"2017","unstructured":"Melchior JT, Street SE, Andraski AB, Furtado JD, Sacks FM, Shute RL, et al. Apolipoprotein A-II alters the proteome of human lipoproteins and enhances cholesterol efflux from ABCA1. J Lipid Res. 2017;58(7):1374\u201385.","journal-title":"J Lipid Res"},{"issue":"9","key":"1350_CR28","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1080\/14789450.2019.1650645","volume":"16","author":"GE Ronsein","year":"2019","unstructured":"Ronsein GE, Vaisar T. Deepening our understanding of HDL proteome. Expert Rev Proteomic. 2019;16(9):749\u201360.","journal-title":"Expert Rev Proteomic"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-020-01350-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-020-01350-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-020-01350-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T19:13:49Z","timestamp":1629486829000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-020-01350-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,21]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1350"],"URL":"https:\/\/doi.org\/10.1186\/s12944-020-01350-3","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,21]]},"assertion":[{"value":"14 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The National Heart, Lung, and Blood Institute\u2019s Institutional Review Board approved this study. All volunteers provided written informed consent for participation. ClinicalTrials.gov identifier: NCT02322203.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"190"}}